Search results for " randomized controlled trial"

showing 10 items of 54 documents

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of …

2011

Purpose The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. Patients and Methods All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the ana…

OncologyMaleCancer ResearchColorectal cancerMESH : AgedKaplan-Meier EstimateMESH : Randomized Controlled Trials as Topiclaw.invention[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRandomized controlled triallawMESH : FemaleStage (cooking)Neoplasm MetastasisMESH: Models TheoreticalMESH : Rectal NeoplasmsSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARandomized Controlled Trials as TopicMESH: Aged0303 health sciencesMESH: Middle AgedMESH : Neoplasm Recurrence LocalAge FactorsMiddle AgedMESH : Adult3. Good healthEuropeOncology030220 oncology & carcinogenesisMESH : Neoplasm MetastasisFemaleMESH: Neoplasm Recurrence LocalAdultmedicine.medical_specialtyMESH : Sex FactorsMESH : MaleMESH : Europe[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Kaplan-Meier Estimate03 medical and health sciencesRECTAL CANCERSex FactorsMESH: Sex FactorsInternal medicinemedicineHumansMESH : Middle AgedSurvival analysisMESH: Kaplan-Meier Estimate030304 developmental biologyAgedMESH: Age FactorsMESH: HumansProportional hazards modelbusiness.industryRectal NeoplasmsMESH : Models TheoreticalMESH : HumansMESH: Rectal NeoplasmsMESH: AdultNomogramModels Theoreticalmedicine.diseaseMESH: Neoplasm MetastasisMESH: MaleSurgeryClinical trialMESH: Randomized Controlled Trials as TopicMESH : Age FactorsMESH: EuropeNeoplasm Recurrence LocalbusinessMESH: FemaleChemoradiotherapy
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

Sorafenib: from literature to clinical practice

2013

Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further …

OncologyTime Factorsadverse eventPharmacologySystemic therapylaw.inventionTranslational Research Biomedicalobservational studieAntineoplastic AgentRandomized controlled trialRisk FactorslawMolecular Targeted TherapyHCCTranslational Medical Researchadverse events; clinical practice; observational studies; randomized clinical trials; sorafenib; Animals; Antineoplastic Agents; Carcinoma Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Molecular Targeted Therapy; Translational Medical ResearchRandomized Controlled Trials as TopicEvidence-Based MedicineLiver NeoplasmsHematologyclinical practiceTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaHumanmedicine.drugNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorProtein Kinase InhibitorAntineoplastic AgentsInternal medicinemedicineAnimalsHumansAdverse effectProtein Kinase InhibitorsneoplasmsNeoplasm StagingAnimalbusiness.industryPhenylurea CompoundsRisk FactorEvidence-based medicinerandomized clinical trialmedicine.diseasedigestive system diseasessorafenibObservational studyLiver functionbusiness
researchProduct

Carbohydrate quality changes and concurrent changes in cardiovascular risk factors: a longitudinal analysis in the PREDIMED-Plus randomized trial.

2020

[Background]: Overall quality of dietary carbohydrate intake rather than total carbohydrate intake may determine the risk of cardiovascular disease (CVD).

PREDIMED-Plus carbohydrate carbohydrate quality index cardiovascular disease fiber glycemic index obesity randomized controlled trialsMaleobesity030309 nutrition & dieteticsMedicine (miscellaneous)030204 cardiovascular system & hematologyOverweightchemistry.chemical_compound0302 clinical medicinecardiovascular diseaseRisk FactorsSurveys and QuestionnairesGlycemic indexLongitudinal StudiesProspective Studies2. Zero hunger0303 health sciencesNutrition and DieteticsMiddle AgedCardiovascular disease3. Good healthGlycemic indexCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsFemalemedicine.symptomfibermedicine.medical_specialtyWaistCarbohydrates03 medical and health sciencesInternal medicinemedicineDietary CarbohydratesHumansFiberObesityAgedCarbohydrate quality indexTriglyceridebusiness.industryPREDIMED-PlusOverweightmedicine.diseaseObesityDietBlood pressurechemistrycarbohydratecarbohydrate quality indexglycemic indexGlycated hemoglobinMetabolic syndromebusinessEnergy Intake
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct

Protective ventilation with high versus low positive end-expiratory pressure during one-lung ventilation for thoracic surgery (PROTHOR): study protoc…

2018

Postoperative pulmonary complications (PPC) may result in longer duration of in-hospital stay and even mortality. Both thoracic surgery and intraoperative mechanical ventilation settings add considerably to the risk of PPC. It is unclear if one-lung ventilation (OLV) for thoracic surgery with a strategy of intraoperative high positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM) reduces PPC, compared to low PEEP without RM.PROTHOR is an international, multicenter, randomized, controlled, assessor-blinded, two-arm trial initiated by investigators of the PROtective VEntilation NETwork. In total, 2378 patients will be randomly assigned to one of two different intraoperative me…

Positive-Pressure RespirationMechanical ventilation; one-lung ventilation; positive end-expiratory pressure; postoperative pulmonary complication; recruitment maneuver; thoracic surgery; Humans; Intraoperative Complications; One-Lung Ventilation; Positive-Pressure Respiration; Research Design; Sample Size; Thoracic Surgical Procedures; Randomized Controlled Trials as TopicResearch DesignSample SizeHumansCorrectionThoracic Surgical ProceduresIntraoperative ComplicationsOne-Lung VentilationRandomized Controlled Trials as TopicTrials
researchProduct

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

2014

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real …

Pulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyAsthma; COPD; Randomized controlled trials; Real life studies; Asthma; Confounding Factors (Epidemiology); Humans; Pulmonary Disease Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Alternative medicineSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary DiseasePulmonary Disease Chronic ObstructiveRandomized controlled triallawIntervention (counseling)medicineCOPDHumansPharmacology (medical)Generalizability theoryMedical physicsInternal validityReal life studiesRandomized Controlled Trials as Topicbusiness.industryBiochemistry (medical)Gold standardConfounding Factors EpidemiologicVariance (accounting)Confounding Factors (Epidemiology)AsthmaReal life studieRandomized controlled trials; Real life studies; Asthma; COPDRandomized controlled trialResearch DesignRandomized controlled trialsPhysical therapybusinessStrengths and weaknesses
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct

Ten important articles on noninvasive ventilation in critically ill patients and insights for the future: A report of expert opinions

2017

Background Noninvasive ventilation is used worldwide in many settings. Its effectiveness has been proven for common clinical conditions in critical care such as cardiogenic pulmonary edema and chronic obstructive pulmonary disease exacerbations. Since the first pioneering studies of noninvasive ventilation in critical care in the late 1980s, thousands of studies and articles have been published on this topic. Interestingly, some aspects remain controversial (e.g. its use in de-novo hypoxemic respiratory failure, role of sedation, self-induced lung injury). Moreover, the role of NIV has recently been questioned and reconsidered in light of the recent reports of new techniques such as high-fl…

Research Reportmedicine.medical_specialtyExacerbationCritical CareCPAP; Non invasive ventilation; Respiratory failure; Critical Care; Critical Illness; Expert Testimony; Forecasting; Humans; Noninvasive Ventilation; Randomized Controlled Trials as Topic; Research Report; Surveys and Questionnaires; Anesthesiology and Pain MedicineCritical IllnessCPAP; Non invasive ventilation; Respiratory failure; Anesthesiology and Pain MedicinePatient characteristicsLung injuryRespiratory failure[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractlaw.inventionlcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineRandomized controlled triallawCPAPAnesthesiologySurveys and QuestionnairesSettore MED/41 - ANESTESIOLOGIAmedicineHumans030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineExpert TestimonyRandomized Controlled Trials as TopicNoninvasive VentilationCritically illbusiness.industryNon invasive ventilation3. Good healthAnesthesiology and Pain Medicine030228 respiratory systemRespiratory failurelcsh:AnesthesiologyCritical Illne[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractNoninvasive ventilationCPAP; Non invasive ventilation; Respiratory failurebusinessHumanResearch ArticleForecasting
researchProduct